Clifford Stocks from Calistoga discusses their acquisition by Gilead

Ian Nicholson of Chroma Therapeutics discusses their recent deal with CTI

Kerstin Valinder explains Nycomed’s transformation from local Scandinavian company to Global Pharma Company

Finn Benned Hansen discusses Novo Nordisk’s focus on finding novel compounds and new delivery methods

Luc Dochez on why Prosensa’s exon skipping therapy is personalised medicine in its ultimate form